Research Topics
| S KunwarSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studiesSandeep Kunwar
Department of Neurosurgery, University of California, San Francisco, California 94143 0350, USA
Neurosurg Focus 20:E15. 2006..Cintredekin besudotox (also known as IL13- PE38QQR) is a recombinant chimeric cytotoxin consisting of interleukin-13 and a truncated exotoxin produced by the Pseudomonas aeruginosa bacterium, which targets malignant glioma cells...- Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studiesS Kunwar
Department of Neurological Surgery, University of California, San Francisco, CA 94143 0112, USA
Acta Neurochir Suppl 88:105-11. 2003..The preclinical data and details and preliminary results of the three clinical trials are reviewed... - Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study GroupSandeep Kunwar
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143 0350, USA
J Clin Oncol 25:837-44. 2007..We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG)... - Endoscopic adjuncts to intraventricular surgerySandeep Kunwar
Department of Neurosurgery, University of California, San Francisco School of Medicine, 505 Parnassus Avenue, Box 0112, San Francisco, CA 94143, USA
Neurosurg Clin N Am 14:547-57. 2003..Its further use in the management of intraventricular cysts and tumors is dependent on long-term follow-up and the development of even better instrumentation... - Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant gliomaIan F Parney
Department of Neurological Surgery, Brain Tumor Research Center, University of California at San Francisco, California 94143-0350, USA
J Neurosurg 102:267-75. 2005.... 
Pituicytoma: characterization of a unique neoplasm by histology, immunohistochemistry, ultrastructure, and array-based comparative genomic hybridizationJoanna J Phillips
Neuropathology Unit, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0102, USA
Arch Pathol Lab Med 134:1063-9. 2010..This pattern of genetic changes only partially overlaps with the genomic alterations reported in pituitary adenomas. In summary, our data suggest that pituicytomas are a unique subset of tumors of the sellar region...- Complications of lumboperitoneal shuntsVincent Y Wang
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, USA
Neurosurgery 60:1045-8; discussion 1049. 2007..These shunts can be placed with or without valves. We sought to review the complications associated with the use of LP shunts with the increasing use of horizontal-vertical (HV) valve systems... - Safety and efficacy of the direct endonasal transsphenoidal approach for challenging sellar tumorsNader Sanai
Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, M 779, P O Box 0112, San Francisco, CA 94143, USA
J Neurooncol 87:317-25. 2008..Large macroadenomas (3-4 cm) can still be addressed with this simple, unmodified direct endonasal approach. We present our experience with this unique and challenging patient population... 
Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomasEdward F Chang
Department of Neurological Surgery, Division of Endocrinology, University of California, San Francisco, California 94143, USA
J Neurosurg 108:736-45. 2008..The authors' aim was to determine predictors of recurrence and overall survival and to define patient subgroups that may benefit from radiotherapy...- Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resectionMichael E Sughrue
Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA
Pituitary 12:158-64. 2009..We sought to determine whether preoperative treatment with dopamine agonists alters the outcome of surgical intervention... - Surgical resection and permanent iodine-125 brachytherapy for brain metastasesKim Huang
Department of Radiation Oncology, University of California San Francisco, 505 Parnassus Avenue, Room L 08, San Francisco, CA, 94143 0226, USA
J Neurooncol 91:83-93. 2009..To evaluate the efficacy and toxicity of surgical resection and permanent iodine-125 brachytherapy without adjuvant whole brain radiation therapy (WBRT) for brain metastases... - An approach to the management of patients with residual Cushing's diseaseLewis S Blevins
California Center for Pituitary Disorders, University of California at San Francisco, Room A 808, San Francisco, CA 94143 0350, USA
J Neurooncol 94:313-9. 2009.... - Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastomaSandeep Kunwar
Division of Neuro Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0350, USA
Neuro Oncol 12:871-81. 2010..There was no survival difference between CB administered via CED and GW. Drug distribution was not assessed and may be crucial for evaluating future CED-based therapeutics... - Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE studySabine Mueller
Department of Neurology, University of San Francisco, 350 Parnassus Ave, Suite 609, San Francisco, CA 94117, USA
J Neurooncol 101:267-77. 2011..55; PFS: P = 0.35) or imaging changes on day 43 MRI (P = 0.88). Catheter positioning scores and overall catheter placement scores were not associated with clinical outcome in this large prospective trial... - GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trialsSusan Chang
Neuro Oncology Service, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0350, USA
J Neurooncol 82:211-20. 2007.... - Extended bifrontal craniotomy for midline anterior fossa meningiomas: minimization of retraction-related edema and surgical outcomesJohn H Chi
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA
Neurosurgery 59:ONS426-33; discussion ONS433-4. 2006..The authors have attempted to quantitate retraction-related edema occurring after surgery to determine whether the extra bone removal limits retraction and reduces the chance of brain injury... - Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant gliomaDavid A Larson
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143 0226, USA
Int J Radiat Oncol Biol Phys 54:1397-404. 2002..To assess the outcome of high central dose Gamma Knife radiosurgery plus marimastat in patients with recurrent malignant glioma... - Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migrationNader Sanai
Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, California 94143, USA
Nature 427:740-4. 2004..Unexpectedly, we find no evidence of chains of migrating neuroblasts in the SVZ or in the pathway to the olfactory bulb. Our work identifies SVZ astrocytes as neural stem cells in a niche of unique organization in the adult human brain... - Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasmsM W McDermott
Department of Neurosurgery, University of California, San Francisco, CA, USA
J Neurooncol 69:83-100. 2004..This paper reviews the recent literature and results of the use of brachytherapy and radiosurgery in the management of newly diagnosed and recurrent malignant gliomas... - Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiformeAnjan Misra
Brain Tumor Research Center, Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0808, USA
Genes Chromosomes Cancer 45:20-30. 2006..We identified three candidate regions on chromosome 7 that conferred radiation resistance in our model system... - Brain metastases of breast cancerMichelle E Melisko
Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
Expert Rev Anticancer Ther 5:253-68. 2005..New approaches include chemotherapy combinations, biologic therapies and novel drug-delivery strategies... - The "yo-yo" technique to prevent cerebrospinal fluid rhinorrhea after anterior clinoidectomy for proximal internal carotid artery aneurysmsJohn H Chi
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143-0112, USA
Neurosurgery 59:ONS101-7; discussion ONS101-7. 2006.... - Genetic subgroups of anaplastic astrocytomas correlate with patient age and survivalS Kunwar
Department of Neurosurgery, University of California, San Francisco, California 94143, USA
Cancer Res 61:7683-8. 2001..Our results indicate that genetic events underlie the well-known effects of age on survival in grade III astrocytoma and demonstrate the importance of molecular classification in astrocytic tumors... - Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndromeChienying Liu
Department of Medicine, University of California, San Francisco 94117, USA
Clin Endocrinol (Oxf) 61:478-86. 2004..Tumour localization by CVS did not accurately predict the tumour site at surgery and should not be used to guide surgical resection... - Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomasEdward F Chang
Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA
Pituitary 13:223-9. 2010..Our data suggest that when performed by experienced transsphenoidal surgeons, durable tumor control can be obtained in these frequently locally aggressive tumors with acceptable rates of post-operative morbidity... - Protein biomarker identification in the CSF of patients with CNS lymphomaSushmita Roy
PPD Biomarker Discovery Sciences, LLC, Menlo Park, CA, USA
J Clin Oncol 26:96-105. 2008..Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease. We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions... - Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety resultsMichael A Vogelbaum
Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Neurosurgery 61:1031-7; discussion 1037-8. 2007.... - Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapyMitomu Kioi
Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive MSC 4555, Bethesda, MD 20892, USA
Technol Cancer Res Treat 5:239-50. 2006..Most recently, a randomized controlled Phase 3 clinical trial (PRECISE) with intraparenchymal IL-13 cytotoxin administration was completed and subjects are being monitored for safety and survival... - Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant bJohn H Sampson
Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 65:27-35. 2003..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks... - Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodiesJohn H Sampson
Department of Surgery Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurg Focus 20:E14. 2006..The purpose of this study was to determine if CED would provide a larger volume of distribution (Vd) of a radiolabeled monoclonal antibody (mAb) than a bolus injection... - Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumorsJohn H Sampson
Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 10:320-9. 2008..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients...